Enphys Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Enphys Acquisition Corp. will be delisted from the NYSE after withdrawing its appeal, and will continue trading on the OTC Pink Marketplace.
Enphys Acquisition Corp. reports the immediate resignation of independent director Eva Redhe due to personal reasons, effective September 10, 2024.
Enphys Acquisition Corp. has received notice of delisting from the NYSE due to failing to meet minimum market capitalization requirements and will transition to the OTC market.
Enphys Acquisition Corp. extends its business combination deadline to December 8, 2024, and secures up to $600,000 in funding through promissory notes.
Enphys Acquisition Corp. amended a promissory note, extending its business combination deadline, and secured up to $200,000 in new funding through two promissory notes.
Enphys Acquisition Corp. has issued a promissory note to secure funding for a four-month extension to its business combination deadline.
Enphys Acquisition Corp. shareholders approved an extension to the deadline for completing a business combination to June 8, 2024, with a significant number of shares being redeemed.